C&EN logo The Newsmagazine of the Chemical World
Home Current Issue ChemJobs Join ACS
Support
Latest News
Business
Government & Policy
Science/Technology
Careers and Employment
ACS News
topics
   
Support
 
Support
How to log in
Contact Us
Site Map
   
About C&EN
About the Magazine
How to Subscribe
How to Advertise
Chemcyclopedia

Latest News RSS Feed

latest news RSS feedWhat is this?

   
Join ACS
Join ACS
  Latest News  
  June 20,  2005
Volume 83, Number 25
p. 15
 

BUSINESS

  BASF To Acquire Switzerland's Orgamol
Purchase to boost German firm's exposure to pharmaceutical contract manufacturing
 

RICK MULLIN
   
 
 

BASF has agreed to acquire the Swiss fine and custom chemical manufacturer Orgamol. The move will place the German firm among the top 10 providers of pharmaceutical contract manufacturing services worldwide, according to Martin Laudenbach, head of fine chemicals at BASF.

NO FRILLS Orgamol's contract manufacturing assets include a plant in Evionnaz, Switzerland
BASF has signed a deal with the private owners of Orgamol, who represent about 75% of the shares in the Swiss firm. BASF has scheduled a meeting with employees, who hold the remaining shares, to vote on the offer later this month. Financial details were not disclosed.

With 2004 sales of about $120 million, Orgamol specializes in phosgene and sodium azide chemistry at plants in Evionnaz, Switzerland, and St. Vulbas, France. Both are hazardous chemistries that drugmakers generally leave to contract producers.

Despite the retreat of diversified companies such as Eastman Chemical and Great Lakes Chemical from the sector, BASF views pharmaceutical custom manufacturing as a market with growth opportunity, according to Thomas Möller, the firm’s manager of corporate media relations. “We have broad know-how, lots of technologies, and financial stability to invest in new capacity,” Möller says. “We are also back-integrated, which makes for a very interesting package.” He says Orgamol will fit into BASF’s “Verbund,” or highly integrated, manufacturing and supply infrastructure.

Peter Pollak, a consultant in the field of custom manufacturing, says Orgamol is an attractive acquisition prospect, given its “substantial” exclusive synthesis business with the top 10 European and U.S. pharmaceutical producers, as well as its cost-competitive, “no-frills” manufacturing assets. Pollak also notes the time is right for such a deal, given the death earlier this year of Orgamol’s president and majority shareholder, Laszlo Baum.

“BASF is one of the few companies that believes in the future of fine chemicals and expects above-average growth in this sector,” Pollak says.
 
     
  Chemical & Engineering News
ISSN 0009-2347
Copyright © 2005
 


 
E-mail this article
to a friend
Print this article
E-mail the editor